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ABSTRACT: Nocturnal asthma (NA) is increasing in prevalence, affecting millions of people Genital
herpes is a widespread sexually transmitted infection caused by the herpes simplex viruses (HSV).
Suppressive valacyclovir therapy has been shown to significantly reduce HSV transmission. The
benefits and costs of using valacyclovir to reduce transmission in couples discordant for genital herpes
will be analyzed in order to better inform decision-making. By reducing transmission, the physical and
psychological harms of living with symptomatic genital herpes will be prevented while saving on certain
healthcare costs. However, the large number needed to treat and the low symptomatic rate among
infected individuals may outweigh these benefits. The costs of trying to achieve a significant reduction
in incidence include the psychological harms of identifying asymptomatic individuals through a large
screening program and the economic costs of the antiviral agent and screening. When these issues are
weighed, the high economic costs render a program to reduce incidence unfeasible. Nevertheless, it is
clinically important to consider the consequences of transmission at an individual level. The specific
circumstances that influence the decision to use suppressive therapy are identified.
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INTRODUCTION
Genital herpes is a sexually transmitted infection
prevalent throughout the world (1). Genital infections
with herpes simplex virus types 1 and 2 (HSV 1 and 2)
are common, but infrequently cause noticeable
symptoms. The seroprevalence of HSV-2 was 9.1% in
2000 for Ontario (2) while a prevalence of 21.9%
among individuals older than 12 years was reported in
the United States between 1988-1994 (3). More recently
(1999-2004), Xu et al. (4) reported a seroprevalence of
17.0%. A small proportion of infected individuals
reported a diagnosis of genital herpes; 9.9% in 1988-
1994 and 14.3% in 1999-2004 (4). Thus, most infected
individuals are unaware that they are infected but are
still able to spread the virus asymptomatically, serving
as important transmitters of the virus.
Genital HSV-1 infections can also occur. Although
HSV-1 typically causes oropharyngeal lesions and is
usually transmitted by non-sexual contact during
childhood (5), the virus can cause genital herpes when
transmitted by vaginal or oral sex, often without visible
lesions (5-8). The lesions of HSV-1 are clinically
indistinguishable from those of HSV-2 (9). However,
HSV-1 genital herpes infections are less severe and
recur less often than HSV-2 (9-12). Howard et al. (2)
found a seroprevalence of 51.1% for HSV-1 in 2000 for
Ontario. Similarly in the US, HSV-1 was widespread in
1999-2004 (57.7%), but the number of HSV-1 infected
individuals reporting genital herpes was 1.8% in this
time period (4). HSV-1 comprises 10-15% of all genital
herpes cases in the US, although regional variations
exist (13). Increasing prevalence of HSV-1 genital
herpes has been observed within specific populations.
For instance, in an American university student
population, the percentage of genital herpes due to
HSV-1 increased from 30.9% in 1993 to 77.6% in 2001
(14).
The high prevalence of genital infections due to both
HSV-1 and HSV-2 suggests a need to reduce the
transmission of genital herpes. In 2003, the US Food
and Drug Administration approved an indication for
Valtrex (valacyclovir) to reduce genital herpes
transmission: “Valtrex reduces the risk of heterosexual
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for these savings to balance the cost of the program was
also determined. It was assumed that the 30% reduction
in incidence occurred immediately.
In addition, the cost (2000 US dollars) of preventing
a single transmission of HSV-2 genital herpes by using
suppressive valacyclovir therapy was calculated (Table
2). Although the number needed to treat to prevent one
transmission varies among studies, the figure used in
this analysis was considered a conservative estimate.
The lifetime savings from preventing the single
transmission was calculated using the larger lifetime
cost to treat men. Further, there would again be
potential savings from a reduction in symptoms among
those receiving suppressive valacyclovir therapy. It
should also be noted that this simplified analysis is
limited since it is based on data from heterogeneous
sources, each with its own methodologies and
assumptions. 
RESULTS AND DISCUSSION
Benefits
The primary benefit of using suppressive valacyclovir
therapy is to reduce transmission within discordant
couples. Corey et al. (17) found that prescribing
valacyclovir to individuals with symptomatic, recurrent
HSV-2 infections the acquisition of genital herpes in
their discordant partner was reduced from 3.6% in the
placebo group to 1.9% in the valacyclovir group (hazard
ratio 0.52; 95% confidence interval 0.27-0.99; P =
0.04). Since the absolute reduction was not large, the
yearly number needed to treat was 38. Individuals in the
valacyclovir group received 500 mg of valacyclovir
once daily for eight months. This therapy effectively
reduced viral shedding relative to the placebo group. As
a result, it reduces transmission when the source partner
does not have any recognizable symptoms but is still
shedding virus, which is when most transmission events
occur (18,19). The potential benefits of using
suppressive valacyclovir to reduce transmissions are
obvious: reducing the psychological and physical harms
of acquiring genital herpes, while lowering the
economic costs associated with this infection. 
transmission of genital herpes to susceptible partners
with healthy immune systems when used as suppressive
therapy in combination with safer sex practices.” (15)
The same indication was approved by Health Canada in
2004 (16). Extensive marketing directed toward patients
encourages them to have their HSV serostatus
determined (and indirectly encourages valacyclovir use
in discordant couples).  Both the positive and negative
aspects associated with using valacyclovir suppressive
therapy to prevent transmission in couples discordant
for HSV will be discussed in this paper in an attempt to
better inform decision-making.
METHODS
A literature review was performed to determine the
costs and benefits of suppressive valacyclovir therapy.
In addition, the cost of using valacyclovir to achieve a
30% reduction in the population incidence of HSV-2
genital herpes was calculated (Table 1). Data was used
from previously published articles, and all costs were
converted to 2000 US dollars. For this analysis, the drug
cost required for a coverage level of 30% was
determined. At such a high coverage, there would be
fewer outbreaks among those receiving suppressive
valacyclovir. These savings were conservatively
calculated by multiplying the annual cost of genital
herpes by the percentage of individuals assumed to have
no recurrent symptoms as a result of receiving
valacyclovir suppressive therapy. This calculation
assumed that all individuals receiving valacyclovir were
symptomatic before treatment. Next, the lifetime
savings from reducing the annual incidence of HSV-2
by 30% was calculated. The number of years required
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Table 1. Calculating the cost (2000 US dollars) of using suppressive
valacyclovir therapy to achieve a 30% reduction in the population
incidence of HSV-2 genital herpes.
Population in USA 2000 (72) $281,421,906.00
Population with HSV-2 (17%) (4) $47,841,724.00
30% of population with HSV-2  $14,352,517.00
Yearly drug costs per individual $1,168.30
Drug costs at 30% coverage $16,768,045,850.00
Yearly lifetime incident cost (51) $1,800,000,000.00
Yearly savings from preventions $540,000,000.00
Cost of genital herpes per year (32) $1,353,405,133.00
Savings due to fewer individuals
seeking medical care, assuming
67% of covered individuals will
have no recurrence (57) $272,034,432.00
3 years of savings $816,103,295.00
3 years of drug therapy $50,304,137,550.00
Net cost $49,488,034,255.00
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individuals with HSV-2 develop recognizable,
symptomatic genital herpes (4), and as a result, the
functional effect of reducing transmission on decreasing
this burden is limited.
Costs
There are numerous costs associated with suppressive
valacyclovir therapy in couples discordant for genital
herpes. First, patients may replace safe sex practices
with such therapy. Condoms offer significant, but not
complete, protection against HSV-2 (33,34). Condoms
also protect against other sexually transmitted
infections that an individual in the relationship may
have. However, Corey et al. (17) found a similar rate of
condom use between the valacyclovir and placebo
groups, and regardless of suppressive therapy, condom
use remains low among discordant couples (19,33).  It
appears that suppressive valacyclovir therapy does not
change couples’ sexual behaviours, but further studies
are required to adequately explore this relationship.
Furthermore, it may be suggested that suppressive use
of valacyclovir will cause antiviral resistance. Despite a
lack of long-term studies, no resistance to this drug has
been found for therapy lasting one year (35-37). In
long-term studies with acyclovir, resistance is
uncommon in immunocompromised individuals (~5%)
and rare in immunocompetent individuals (38,39).
Currently, there appears to be little physical harm in
taking valacyclovir every day for more than a year in
healthy patients (35-37). In patients infected with
human immunodeficiency virus (HIV), there are no data
on the safety of therapy lasting more than 6 months
(40). Headaches, nausea and vomiting, dizziness, and
abdominal pain are the most commonly reported
adverse effects. Psychologically, taking a drug every
day may cause harm or distress. Although patients with
recurrent genital herpes prefer suppressive over
episodic therapy (22), it is not known how
asymptomatic patients would respond to and comply
with daily therapy over the long-term.
As previously described, there would be some
financial savings with suppressive valacyclovir therapy,
but there would also be significant economic costs
associated with this program due to drug costs and
screening (31,32,41). Firstly, valacyclovir costs $118.47
for 30 tablets of 500 mg, totaling $1441 a year
(Canadian dollars, 2008). Another significant cost
would be identifying those individuals that have an
asymptomatic or unrecognized clinical infection.
According to Corey (42), 60% of HSV-2 seropositive
individuals have unrecognized symptoms, while 20%
are subclinical (asymptomatic) with another 20% being
recognized symptomatic. However all three groups
have similar frequencies of asymptomatic shedding
Psychologically, acquiring symptomatic genital
herpes can have a significant emotional impact on
patients (20-22). Such patients may suffer from social
isolation and have difficulty initiating relationships
(23,24). In contrast, other studies have shown that
appropriate counseling can significantly reduce the
psychological harm caused by diagnosing genital
herpes (25-27). Receiving genital herpes can also cause
anger towards the source partner. Additionally, the
source partner may be significantly worried about
transmitting genital herpes to their non-infected partner
(23). Therefore by reducing transmission, valacyclovir
can diminish possible psychological harms, although
counseling has been shown to be effective in this regard
as well (26).
Potential physical harms due to genital herpes can be
prevented with suppressive therapy, assuming that the
partner acquires a recognizable, symptomatic infection.
Genital herpes caused by HSV-1 recurs infrequently and
the frequency decreases over time with a recurrence
duration of 7 days (12,28). In contrast, HSV-2 genital
herpes recurs more frequently and the rate of recurrence
decreases slowly over time with a recurrence duration
of 8.5 - 10.1 days (28-30). Local symptoms for HSV-2
infection include pain, itching, and vaginal or urethral
discharge (30). Fever, headache, and malaise occur in
39% of men and 68% of females during primary
infection (30). Pain during recurrent genital herpes is
reported as severe in 11% of patients, moderate in 36%,
mild in 48%, and absent in 4% (21). Complications of
genital herpes include dysuria, aseptic meningitis,
autonomic nervous system dysfunction, transverse
myelitis, yeast infections, and extragenital lesions (30).  
Economically, reducing the population incidence of
genital herpes will decrease such healthcare costs as
hospitalizations, clinical examinations, consultations,
and tests. Indirect economic costs for patients, such as
time off work and traveling costs, will also be avoided
(21,23,31,32). Recurrent genital herpes can also lower
work effectiveness during severe symptomatic events
(21). Szucs et al. (32) performed an analysis of the
economic burden of genital herpes in the US for 1996.
They estimated the cost of genital herpes to range from
$283 million (0.1% of the US health care expenditure)
to $984 million with indirect costs totaling an additional
$214 million. Of the total cost, 49.7% came from drug
expenditures, 47.7% from medical care (consultations
and lab testing), and 2.6% from hospital costs. Szucs
and colleagues (32) also calculated a cost of $60 000 per
case of neonatal herpes and $2 500 for each cesarean
section. In summary, reducing transmission will
diminish the psychological, physical, and certain
economic burdens of symptomatic genital herpes.
However, it should be noted that only 14.3% of42 2009
proportion of patients diagnosed and the proportion of
diagnosed that are receiving therapy. With a coverage
level of 3.2% (the current coverage in the US) and 3
years of valacyclovir therapy, it is expected that there
would be a 1.8% reduction in new cases after 5 years
and a 2.8% reduction after 25 years (50). The percent
reduction of new cases increases to 65% with a
coverage of 60% after 25 years. According to Williams
et al. (50), a coverage rate of 60% is unrealistic, but they
suggest that a coverage rate of 30% is theoretically
possible and would reduce incidence by 30% after 25
years. Additionally, the duration of suppressive therapy
can be increased. At a coverage level of 3.2%, the
incidence of HSV-2 infection would be expected to
decrease by 3.5% after 25 years with 5 years of therapy,
compared to 1.3% with a 1-year therapy program. 
The financial cost of administering suppressive
valacyclovir over three years to 30% of Americans with
HSV-2 genital herpes is approximately $50.3 billion
(Table 1). By treating such a large number of patients
with suppressive therapy, it is estimated that $816
million would be saved over the three years from
reduced outbreaks among infected individuals. Thus,
the net cost of a three-year program is $49.5 billion.
Using the lifetime cost of an individual with genital
herpes (51), the yearly savings from the 30% reduction
in incidence is $540 million. Therefore, the savings
from the program would balance the cost after 92 years. 
Obviously, one must also consider the increased
quality of life gained from a decrease in incidence. A
conservative estimate of the cost to prevent one HSV-2
transmission is $12,932 (Table 2). This cost would
outweigh the benefits gained since a cost of $8,200 per
prevention translates to $140,000 per quality-adjusted-
life-year gained, which is above the cost effective
threshold of $50,000-$100,000 (52). Moreover, these
calculations do not include the screening costs that
would be necessary to identify asymptomatic
individuals and reach the 30% coverage rate. Such
screening would be essential to this program because
they are the majority of individuals with genital herpes
and the main group transmitting the virus (42,46). The
compliance may also be lower in the general public than
in the trial performed by Corey et al. (17), especially
among asymptomatic or unrecognized patients (50). 
Cost-benefit analyses: individual
At an individual level in Canada, the financial costs
would be that of valacyclovir, $1441 each year, and the
cost of screening to determine whether individuals are
infected and if couples are discordant. The potential for
overuse of expensive serologic testing is enormous. The
psychological and physical benefits noted above may
convince a symptomatic, discordant couple into asking
events (19), defined as detection of HSV on the surface
of skin or mucosa in the absence of genital lesions (43).
Most individuals with unrecognized symptomatic
genital herpes can identify their symptoms with
counseling and education (42,44). Additionally, type-
specific serologic tests are capable of distinguishing
between HSV-1 and HSV-2 (45). The presence of
antibodies to HSV-1 alone gives no information on the
presence of genital herpes because the site of the
infection, oral or genital, cannot be determined (26).
Since HSV-1 is very common, genital herpes due to
HSV-1 would be difficult to detect without swabbing
genital lesions. In addition, the frequency of testing
required to identify individuals with genital herpes adds
to the cost of screening (45). If testing were
recommended with every new sexual partner, there
would be considerable strain placed on the healthcare
system and the patient. 
Moreover, it is predicted that there would be
significant psychological harm associated with
diagnosing patients with genital herpes who were
previously unaware of their infection. Through a large
screening program, physicians may actually cause more
psychosocial harm to asymptomatic individuals, such as
social isolation and reluctance to initiate relationships,
than the physical harms these individuals experience
(23,24,46,47). However as previously noted, studies
have shown that counseling is effective in reducing
psychological harm upon diagnosis (25,26). In addition,
disclosing the problem to their current partner, who may
raise questions of infidelity or past sexual history, may
damage or ruin the relationship. Due to the additional
economic cost and psychological problems of screening
the general population, “it would not be useful.
Screening of targeted populations, however, may be
appropriate.” (48) That is, a diagnosis would be more
important in couples where transmission would be
significantly harmful. Such circumstances may include
individuals who are at increased risk of HIV infections,
HIV positive patients, and patients with a partner with
genital herpes (48). By diagnosing these individuals
with genital herpes, infected individuals may recognize
outbreaks and abstain during such periods. In fact,
transmission rates may decrease after source partners
disclose (49). 
Cost-benefit analyses: population
Current models suggest that suppressive therapy will
have a minimal effect on reducing the population
incidence of genital herpes at the currently low levels of
diagnosis and treatment (50). The coverage level and
the duration of suppressive therapy are important
factors in reducing the population incidence (50). The
coverage level is primarily determined by the
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HSV-2, asymptomatic shedding was three fold more
frequent during the first three months after resolution of
primary infection than after these three months (11). It
is also important to discuss the number of sexual
partners and the nature of the relationship. Between
1999-2004, the seroprevalence of HSV-2 was 39.9% in
individuals who had 50 or more lifetime partners
compared to 3.8% who had one lifetime partner (4).
Transmission is most common in relationships lasting
1-6 months (49).
Transmitting genital herpes may increase the
receptive partner’s risk of contracting HIV in the future.
The risk of acquiring HIV is approximately three times
greater in HSV-2 infected men or women (60). The
suggested mechanism for this interaction is likely due to
the destruction of the epithelial layer by HSV-2 and
attraction of CD4-positive cells (61). This relationship
is important for partners that may have a higher risk of
contracting HIV due to location, drug use, or sexual
behaviours. Additionally, special consideration should
be given to a HIV positive, HSV-2 negative partner
because HSV-2 reactivation correlates with increased
plasma HIV-1 levels (62,63). HSV-2 can increase
morbidity and mortality for HIV infected people and
may accelerate the course of HIV disease (64). HSV-2
positive, HIV-1 positive individuals may also be more
efficient at transmitting HIV than HSV-2 negative
individuals (64). Thus, it is important to prevent
transmission of HSV-2 to HIV positive individuals
(65,66). The interaction between HSV-1 and HIV has
yet to be adequately explored (67). 
Couples involving a HSV-negative pregnant woman
and a HSV positive partner should be made aware that
vertical transmission (genital HSV-1 and HSV-2) can be
serious for infants, causing death or neurological
impairment from disseminated infection of multiple
organs and the central nervous system (47,68). Disease
of the skin, eyes, or mouth can also occur (68).
However, the highest risk of neonatal injury occurs
when the pregnant woman acquires either virus type
near the time of labor (69). The emotional and financial
costs of vertical HSV transmission are obviously
significant (31). The duration of the relationship is
important, with an 8-fold risk in transmitting HSV-2 in
relationships of one year or less compared to
relationships existing for more than one year (8).
Besides suppressive valacyclovir therapy, counseling,
condom use, and abstinence are strategies that should
reduce the risk of transmission. However, few
discordant couples adopt safer sex practices when
educated (70). Similar disseminated infections can
occur in immunosuppressed individuals. Thus, such
individuals entering relationships with HSV positive
partners may benefit from suppressive therapy for the
for valacyclovir to reduce the likelihood of
transmission, but in how many instances will
valacyclovir reduce transmission? Corey et al. (17)
found a 48% reduction in the risk of transmission, but
this reduction was from an acquisition risk of 3.6% to
1.9%. Thus, transmission is a rare event without
valacyclovir use. Furthermore, when transmission does
occur, most people do not develop symptomatic genital
herpes. It is essential that patients understand these facts
in order to make an informed decision. 
Clinically, it is important to consider cases on an
individual basis. Specific couple characteristics affect
the significance of genital herpes transmission. These
factors must be discussed before a discordant couple
makes a decision regarding suppressive valacyclovir
therapy. For example, prescription may depend on the
HSV-1 serostatus of the partner without genital herpes.
If this individual has HSV-1, they have a lower
probability of developing symptomatic genital herpes
upon acquiring HSV-2 (30,53-55). 
In addition, the virus type (HSV-1 or HSV-2) of the
source partner may be important to determine because
each type causes different symptoms and has different
modes of transmission. Type 1 (genital) is less likely to
cause recurrent symptoms for the partner that acquires
symptomatic infection (9-12). Compared to HSV-2,
there is less asymptomatic shedding and, therefore, a
reduced transmission rate with type 1 genital herpes
(11). In addition, oral sex from a partner with a history
of oral herpes is a risk factor for HSV-1 transmission (6-
8,56). Transmission can occur without lesions because
virus in the oropharynx can shed asymptomatically
(56). Transmission from oral sex is less likely for HSV-
2 because this virus is not as likely to cause an infection
in the oropharynx (7,13). Moreover, the manifestation
of symptoms in the HSV-2 source partner should be
considered. If an individual has many recurrences each
year, then it would be more feasible to prescribe
suppressive therapy because the individual will receive
the added benefit of reduced symptoms. However,
suppressive valacyclovir therapy is not typically
necessary for HSV-1 genital herpes (12,57), and the
effect of valacyclovir on HSV-1 transmission has not
been adequately explored. Nevertheless, valacyclovir
does decrease the presence of the virus in saliva (58)
and has been examined in transmission between
wrestlers (59).
Another factor to consider is the duration of the
infection in the source partner because infectivity likely
decreases with time due to a decrease in shedding
(11,33). Most infections occur within a year of
contracting the virus. Wald et al. (49) found the mean
number of sex acts before transmission was 40 while
Mertz et al. (18) found a median number of 24. For44 2009
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Finally, it is important to consider the degree of
emotional stress in the source partner regarding
transmission and the emotional problems that would
likely occur in the non-infected partner upon acquiring
genital herpes (71). Some individuals may have a more
negative stigma regarding genital herpes than others
and acquiring it would be severely damaging to these
patients. Such patients should be counseled in an effort
to help them understand genital herpes. Nevertheless,
some couples’ relationships may be severely affected by
this disease and thus may require suppressive
valacyclovir therapy more than other couples.
CONCLUSION
The high prevalence of genital infections with HSV-1
and HSV-2 is of great concern and indicates that a
solution is required. Nevertheless, suppressive
valacyclovir therapy is not a feasible method of
reducing the incidence of genital herpes because of the
overwhelming economic cost and issues of identifying
asymptomatic individuals. Furthermore, the stigma and
fear associated with genital herpes only increases the
need to educate patients. If a symptomatic individual
desires to take suppressive therapy, the physician must
inform the patient about the influence of valacyclovir
on transmission along with the probability that their
partner will become symptomatic. Moreover, patients
should consider certain factors that increase the
importance of transmission when making a decision,
such as the serostatus of the non-infected individual,
type of HSV infection, duration of infection, HIV risk,
HIV serostatus, pregnancy, and likely degree of
resultant emotional stress. Finally, patients need to
know about the realistic clinical harms of HSV
infections. After better understanding the disease by
discussing the above points, patients will be better
positioned to make an informed decision regarding the
use of prophylactic therapies like valacyclovir.  
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